Evaluation of Safety and Dosing of a Vitamin C Bundle for Sepsis Treatment in Africa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-01

Study Completion Date

2021-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-label phase 2a Randomized Controlled Trial (RCT) assessing the pharmacokinetics of two different doses of intravenous vitamin C given alongside vitamin B1 in adult medical patients with sepsis and hypotension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin C & Thiamine to Treat Sepsis and Septic Shock

NCT03592277

Sepsis Septic Shock

COMPLETED PHASE2

Vitamin C Deficiency in Septic Shock

NCT06224881

Septic Shock

COMPLETED PHASE4

Outcome Following Vitamin C Administration in Sepsis

NCT01590303

Severe Sepsis

UNKNOWN PHASE2

High Dose of Vitamin C on Mechanically Ventilated Septic Patients in Intensive Care Unit

NCT04029675

Ventilator Associated Pneumonia ( VAP) Sepsis

COMPLETED NA

Vitamin C and Septic Shock

NCT03338569

Septic Shock Sepsis

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sepsis is a life-threatening infection which, due to a dysregulated host response to infection, is responsible for more than 11 million deaths annually, a large percentage of which occur in sub-Saharan Africa (sSA). Emerging research shows promising benefits in treating sepsis patients with "metabolic resuscitation" using combinations of hydrocortisone, intravenous (IV) ascorbic acid (vitamin C) and IV thiamine (vitamin B1), alone or in combination. Studies are currently underway in the USA, Europe, Asia, and South America to understand whether combinations of these medicines or the medicines individually can improve outcomes for patients with sepsis. Although none of these studies are being conducted in sSA, the medicines comprising these metabolic 'bundles' are inexpensive, readily available and relatively safe to administer. It is critical that similar studies are conducted in sSA to evaluate whether or not these inexpensive medicines (or a combination of them) are efficacious for improved survival among patients with sepsis. If these studies prove that these medicines can improve survival from sepsis, there is a large potential to save many lives. Through the Preparation for Randomised Evaluation of a VItamin C bundle for Sepsis Treatment in Africa (REVISTA-Prep) studies, the investigators intend to conduct preliminary research in Uganda to help define parameters for a future RCT aimed at identifying the optimal vitamin C and vitamin B1 combination for improving survival from sepsis among adults in sSA, where resources are constrained, intensive care units are rare and issues like poverty, malnutrition and HIV are common. The study described in this protocol (i.e., REVISTA-DOSE) aims to establish the optimal vitamin C dosing strategy for the future REVISTA-RCT (assessing the efficacy of variations of a treatment bundle comprising vitamin C/B1 and/or hydrocortisone for reducing mortality among adult patients with sepsis in Africa).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Septic Shock HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravenous vitamin C 1.5g + intravenous vitamin B1

intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours

Group Type EXPERIMENTAL

Vitamin C

Intervention Type DRUG

Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses

Vitamin B1

Intervention Type DRUG

Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses

Intravenous Vitamin C 3g + intravenous vitamin B1

Intravenous vitamin C (3 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours

Group Type EXPERIMENTAL

Vitamin C

Intervention Type DRUG

Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses

Vitamin B1

Intervention Type DRUG

Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses

Usual Care

Usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin C

Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses

Intervention Type DRUG

Vitamin B1

Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ascor Ascorbate Thiamine Thiamin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult (≥18 years old) patients presenting to the emergency department of Kiruddu National Referral Hospital (KNRH) with:

* suspected infection \[(any of): temperature \>38 degrees Celsius or \<36 degrees Celsius or (in the past seven days) fevers, rigors, night sweats or antibiotic use\]; AND
* systolic blood pressure (SBP) \<90 mmHg
2. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
3. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria

1. Pregnant or known active breast feeding
2. Non-severe, localized, uncomplicated infection (e.g., cellulitis with only local symptoms) which is apparent on clinical examination
3. Severe bleeding or hemorrhagic shock
4. Hypotension likely secondary to a cause other than sepsis or sepsis-induced cardiac insufficiency
5. Detainee or prisoner
6. Admission to a surgical or obstetric/gynecological ward
7. Emergency surgery required
8. Previously recruited to the REVISTA-DOSE study
9. History of end stage renal disease requiring dialysis
10. Current symptomatic renal stones or or a previous diagnosis of primary hyperoxaluria or oxalate nephropathy
11. History of allergic reactions to vitamin C or vitamin B1
12. Use of vitamin C at a dose greater than 1 g (oral or intravenous) within 24 hours of screening
13. Chronic disease/illness that, in the opinion of the site investigator, has a lifespan of less than 30 days unrelated to current sepsis diagnosis (e.g., advanced malignancy or neurodegenerative disease).
14. Previous or current enrolment in a trial in which co-enrolment is not allowed

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No